

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WAI YUEN TONG MEDICINE HOLDINGS LIMITED

(位元堂藥業控股有限公司*)

(Incorporated in Bermuda with limited liability)

(Stock Code: 897)

POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 19 OCTOBER 2023

The Board is pleased to announce that the proposed ordinary resolutions set out in the SGM Notice in respect of the Sale and Purchase Agreements and the Transactions were duly passed by the Independent Shareholders at the SGM held on 19 October 2023 by way of a poll.

References are made to (a) the joint announcement dated 8 September 2023 jointly issued by Wai Yuen Tong Medicine Holdings Limited (the “**Company**”), Wang On Group Limited (“**WOG**”) (Stock Code: 1222) and Wang On Properties Limited (Stock Code: 1243); and (b) the circular of the Company dated 29 September 2023 (the “**Circular**”) containing the notice dated 29 September 2023 (the “**SGM Notice**”) convening the special general meeting (the “**SGM**”) held on 19 October 2023. Capitalised terms used herein shall have the same meanings as defined in the Circular unless otherwise defined.

POLL RESULTS OF THE SGM

The Board is pleased to announce that the proposed ordinary resolutions set out in the SGM Notice in respect of the Sale and Purchase Agreements and the Transactions were duly passed by the Independent Shareholders at the SGM held on 19 October 2023 by way of a poll and the poll results are as follows:

Ordinary resolutions set forth in the SGM Notice		Number of Shares (Approximate %)		Total number of Shares voted (%)
		For	Against	
1.	<p>(a) To approve, confirm and ratify the Sale and Purchase Agreement I (as defined in the Circular) and the transactions contemplated thereunder and the implementation thereof; and</p> <p>(b) To approve, confirm and ratify the entering into of the Sale and Purchase Agreement I (as defined in the Circular) and to authorise any one director of the Company (“Director”) to do all such acts and things as the Director in his/her sole and absolute discretion deems necessary, desirable or expedient to implement, give effect to and/or complete the Sale and Purchase Agreement I (as defined in the Circular) and the transactions contemplated thereunder.[#]</p>	34,020,236 (99.99%)	2,455 (0.01%)	34,022,691 (100.00%)
2.	<p>(a) To approve, confirm and ratify the Sale and Purchase Agreement II (as defined in the Circular) and the transactions contemplated thereunder and the implementation thereof; and</p> <p>(b) To approve, confirm and ratify the entering into of the Sale and Purchase Agreement II (as defined in the Circular) and to authorise any one Director to do all such acts and things as the Director in his/her sole and absolute discretion deems necessary, desirable or expedient to implement, give effect to and/or complete the Sale and Purchase Agreement II (as defined in the Circular) and the transactions contemplated thereunder.[#]</p>	34,020,236 (99.99%)	2,455 (0.01%)	34,022,691 (100.00%)

[#] Note: The full text of the above resolutions proposed at the SGM is set out in the SGM Notice.

Tricor Secretaries Limited, the Company's branch share registrar and transfer office in Hong Kong, was appointed as the scrutineer at the SGM for the purpose of vote-taking.

As at the date of the SGM, the total number of issued Shares was 1,171,102,888. As disclosed in the Circular and as at the date of the SGM, WOG was considered to have a material interest in the Sale and Purchase Agreements and the Transactions which was different from other Shareholders; therefore, WOG and its close associates were required to abstain from voting on the ordinary resolutions nos. 1 and 2. Rich Time Strategy Limited (a wholly-owned subsidiary of WOG), being an associate of WOG and holding 810,322,940 Shares, representing approximately 69.19% of the total issued Shares, was required to abstain from voting on the ordinary resolutions nos. 1 and 2. The Board confirmed that Rich Time Strategy Limited had abstained from voting in respect of such resolutions. Accordingly, the total number of Shares entitling the Shareholders to attend and vote on each of the ordinary resolutions nos. 1 and 2 was 360,779,948, representing approximately 30.81% of the total issued Shares.

Save as disclosed above and in the Circular, there were no Shares entitling the Shareholders to attend and abstain from voting in favour as set out in Rule 13.40 of the Listing Rules and there were no parties who have stated their intention in the Circular and the SGM Notice to vote against the above ordinary resolutions or to abstain have done so at the SGM. Ms. Tang Wai Man, an executive Director, and Mr. Li Ka Fai, David, an independent non-executive Director, attended the SGM in person.

By Order of the Board
WAI YUEN TONG MEDICINE HOLDINGS LIMITED
(位元堂藥業控股有限公司*)
Tang Wai Man
Executive Director

Hong Kong, 19 October 2023

As at the date of this announcement, the Board comprises Mr. Tang Ching Ho, Ms. Tang Wai Man and Ms. Law Man Yee, Anita as executive Directors, and Mr. Siu Man Ho, Simon, Mr. Leung Wai Ho, Mr. Cho Wing Mou and Mr. Li Ka Fai, David as independent non-executive Directors.

** For identification purpose only*